Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
LEXINGTON, Mass., Feb. 17, 2016 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will present at the 2016 RBC Capital Markets Global Healthcare Conference on February 24, 2016, at 11:00 a.m. Eastern Time in New York City.
The presentation will be held using a fireside-chat format in which Dr. Ali Fattaey, President and Chief Executive Officer, will provide a brief overview of the Company’s pipeline of drug candidates and business strategy, after which an equity analyst will moderate a question and answer session.
A corresponding webcast of the presentation can be accessed by visiting:
http://www.veracast.com/webcasts/rbc/healthcare2016/88207347337.cfm
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 pathway/ VISTA, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit IRAK4, including CA-4948. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
For more information, visit Curis' website at www.curis.com.
For More Information: Mani Mohindru, Ph.D. Senior Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
